Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2013

01-06-2013 | Review Article

Achieving glycemic control in patients with type 2 diabetes and renal impairment

Authors: Angelo Avogaro, Guntram Schernthaner

Published in: Acta Diabetologica | Issue 3/2013

Login to get access

Abstract

Defining optimal regimens for the management of diabetes among patients with renal impairment is often clinically challenging, and guidance on the optimal management of these patients in clinical practice can vary considerably. Moreover, as many anti-diabetes agents are predominantly excreted renally, treatment options to control blood glucose levels are limited for patients with type 2 diabetes and concomitant chronic kidney disease. Many of the widely used and more established anti-diabetes drugs cannot be used in this population either or must be down-titrated to reduce the increased risk of severe hypoglycemic episodes. A number of more recently available anti-diabetes drugs are indicated for use in patients with type 2 diabetes and chronic kidney disease. Newer drugs that may improve the currently very limited treatment options for patients with type 2 diabetes and renal impairment include the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors. This review paper, based on a literature search for both original and review articles (Medline), relevant clinical practice/regulatory guidelines and integrating our own knowledge of the field, provides an up-to-date examination of the current treatment options available. However, further studies with larger populations of patients with type 2 diabetes and chronic kidney disease are needed to clarify the efficacy and safety of the different treatment options, including newer drugs.
Literature
1.
Bash LD, Selvin E, Steffes M, Coresh J, Astor BC (2008) Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 168:2440–2447PubMedCrossRef
2.
de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM (2011) Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 171:412–420PubMedCrossRef
3.
Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M (2011) Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 171:1920–1927PubMedCrossRef
4.
Narayan KM, Gregg EW, Engelgau MM, Moore B, Thompson TJ, Williamson DF, Vinicor F (2000) Translation research for chronic disease: the case of diabetes. Diabetes Care 23:1794–1798PubMedCrossRef
5.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147PubMedCrossRef
6.
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 suppl 1):S1–S266
7.
8.
Koro CE, Lee BH, Bowlin SJ (2009) Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 31:2608–2617PubMedCrossRef
9.
Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34:1329–1336PubMedCrossRef
10.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int 63:225–232PubMedCrossRef
11.
Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182–187PubMedCrossRef
12.
Fernandez-Real JM, Vendrell J, Garcia I, Ricart W, Valles M (2012) Structural damage in diabetic nephropathy is associated with TNF-alpha system activity. Acta Diabetol 49:301–305PubMedCrossRef
13.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
14.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef
15.
Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32:2068–2074PubMedCrossRef
16.
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419–430PubMedCrossRef
17.
Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, Sharrett AR, Brancati FL, Coresh J (2011) Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 60:298–305PubMedCrossRef
18.
Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R, Zinman B (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:17–30PubMedCrossRef
19.
National Kidney Foundation (2012) KDOQI Clinical Practice Guidelines for Diabetes and CKD: 2012 update. Am J Kidney Dis 60:850–886
20.
Woerle HJ, Meyer C, Popa EM, Cryer PE, Gerich JE (2003) Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity. Diabetes 52:1386–1392PubMedCrossRef
21.
Haneda M, Morikawa A (2009) Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 24:338–341PubMedCrossRef
22.
Jonsson A, Rydberg T, Sterner G, Melander A (1998) Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429–435PubMedCrossRef
23.
24.
Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C (2001) Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147–152PubMedCrossRef
25.
26.
27.
Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–68PubMedCrossRef
28.
29.
Canadian Diabetes Association (2008) Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32(suppl 1):S1–S201
30.
Schernthaner G, Ritz E, Schernthaner GH (2010) Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant 25:2044–2047PubMedCrossRef
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Lipska KJ, Bailey CJ, Inzucchi SE (2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34:1431–1437PubMedCrossRef
44.
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499–1507PubMedCrossRef
45.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef
46.
Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C (2008) Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23:3174–3183PubMedCrossRef
47.
Joss N, Ferguson C, Brown C, Deighan CJ, Paterson KR, Boulton-Jones JM (2004) Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 97:219–227PubMedCrossRef
48.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ (2003) Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542–549PubMedCrossRef
49.
Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892–1899PubMedCrossRef
50.
51.
Malaisse WJ (2006) Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 7:331–337PubMedCrossRef
52.
Scheen AJ (2007) Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46:93–108PubMedCrossRef
53.
Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G (2003) Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 20:642–645PubMedCrossRef
54.
Kendall DM, Cuddihy RM, Bergenstal RM (2009) Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 122:S37–S50PubMedCrossRef
55.
Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367–374PubMedCrossRef
56.
Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317–327PubMedCrossRef
57.
Ferrer-Garcia JC, Martinez-Chanza N, Tolosa-Torrens M, Sanchez-Juan C (2010) Exenatide and renal failure. Diabet Med 27:728–729PubMedCrossRef
58.
Johansen OE, Whitfield R (2008) Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 66:568–569PubMedCrossRef
59.
Weise WJ, Sivanandy MS, Block CA, Comi RJ (2009) Exenatide-associated ischemic renal failure. Diabetes Care 32:e22–e23PubMedCrossRef
60.
Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68:898–905PubMedCrossRef
61.
Davidson JA, Brett J, Falahati A, Scott D (2010) Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 6:1–31
62.
Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13:947–954PubMedCrossRef
63.
Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10:545–555PubMedCrossRef
64.
Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862–1864PubMedCrossRef
65.
Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ (2011) Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 13:939–946PubMedCrossRef
66.
Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I (2011) Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 13:523–532PubMedCrossRef
67.
68.
Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335–1343PubMedCrossRef
69.
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54:516–523PubMedCrossRef
70.
Marney A, Kunchakarra S, Byrne L, Brown NJ (2010) Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56:728–733PubMedCrossRef
71.
Metadata
Title
Achieving glycemic control in patients with type 2 diabetes and renal impairment
Authors
Angelo Avogaro
Guntram Schernthaner
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-012-0442-x

Other articles of this Issue 3/2013

Acta Diabetologica 3/2013 Go to the issue

Original Article

Systemic exposure to Pseudomonal bacteria: a potential link between type 1 diabetes and chronic inflammation

Original Article

Lipid accumulation in overweight type 2 diabetic subjects: relationships with insulin sensitivity and adipokines

CONSENSUS PAPER

Trialogue

Original Article

Polymorphisms in the Selenoprotein S gene and subclinical cardiovascular disease in the Diabetes Heart Study

Original Article

Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women

Short Communication

Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits